Overview
- Kenvue, which reported results Thursday, posted adjusted earnings of 32 cents a share and $3.91 billion in sales, both above Wall Street estimates.
- The Skin Health and Beauty unit, home to Neutrogena and Aveeno, led growth with sales up 8.4% to $1.06 billion.
- Profitability improved as adjusted gross margin rose 80 basis points to 60.8% and operating margin reached 24.0% on supply-chain gains and pricing.
- Management expects about $250 million in pre-tax restructuring charges this year tied to its transformation plans.
- The company withheld guidance because it is being bought by Kimberly-Clark for $40 billion, with closing targeted for the second half of 2026 subject to foreign regulatory approvals.